Pliant Therapeutics Inc [PLRX] stock is trading at $3.00, up 0.67%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PLRX shares have gain 15.16% over the last week, with a monthly amount drifted -73.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pliant Therapeutics Inc [NASDAQ: PLRX] stock has seen the most recent analyst activity on February 10, 2025, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $4 from $41. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on February 10, 2025, and dropped its price target to $4. On February 10, 2025, downgrade downgraded it’s rating to Perform. JP Morgan downgraded its rating to a Neutral. H.C. Wainwright downgraded its rating to a Neutral. Citigroup downgraded its rating to Neutral for this stock on February 10, 2025, and downed its price target to $4. In a note dated February 10, 2025, Canaccord Genuity downgraded an Hold rating on this stock and revised its target price from $43 to $4.
Pliant Therapeutics Inc [PLRX] stock has fluctuated between $2.43 and $18.00 over the past year. Currently, Wall Street analysts expect the stock to reach $35.5 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $3.00 at the most recent close of the market. An investor can expect a potential return of 1083.33% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -45.88%, Pretax Profit Margin comes in at -41.67%, and Net Profit Margin reading is -41.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.49 and Total Capital is -0.55. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.92 points at the first support level, and at 2.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.09, and for the 2nd resistance point, it is at 3.19.
Ratios To Look Out For
For context, Pliant Therapeutics Inc’s Current Ratio is 10.26. Further, the Quick Ratio stands at 10.26, while the Cash Ratio is 1.99.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jan 17 ’25 when 52419.0 shares were sold. Chief Financial Officer, Cummings Keith Lamont completed a deal on Jan 17 ’25 to sell 20148.0 shares. Meanwhile, Chief Business Officer Hull Hans sold 15936.0 shares on Jan 17 ’25.
